High-Sensitivity Troponin T: A Biomarker for Diuretic Response in Decompensated Heart Failure Patients

Table 1

Population characteristics and comparison of clinical variables, laboratory results, and medications between admission day (day 1) and day 3.

Age (yrs)	76,0 ± 10,88
Male sex—%	39
Diabetes mellitus—%	45
Glycated HgB (%)	7,02 ± 0,96
COPD—%	17
Dementia—%	12
Sleep apnea—%	18
Noninvasive ventilation—%	17
Ischemic heart disease—%	50
Atrial fibrillation—%	59
LV ejection fraction (%)	43,46 ± 11,73
LV ejection fraction ≥40%—%	68
	Day 1	Day 3	value
Body mass index (Kg/m^2)	29,44 ± 6,17	28,35 ± 6,23	<0,001
Heart rate (bpm)	93,65 ± 24,35	76,41 ± 11,96	<0,001
SBP (mmHg)	139,79 ± 25,86	121,97 ± 16,2	<0,001
Plasma creatinine (mg/dL)	1,04 [0,89–1,31]	1,06 0,85–1,40	0,082*
eGFR (mL/min/1,73 m^2)	58,0 [44,0–72,0]	58,0 39,25–72,75	0,171*
Plasma urea (mg/dL)	55,21 ± 20,84	62,3 ± 25,47	0,001
Serum potassium (mmol/L)	4,03 ± 0,51	4,04 ± 0,54	0,95
Serum sodium (mmol/L)	140,54 ± 4,38	140,68 ± 3,95	0,72
Hemoglobin (g/dL)	12,43 ± 2,07	—	—
Albumin (mg/dL)	3,68 ± 0,40	—	—
NTproBNP (pg/mL)	2750 [1672–6032]	1835 902–3837	<0,001 *
hsTnT (ng/mL)	0,033 [0,019–0,050]	0,030 0,018–0,051	0,039 *
IV furosemide—%	100	37	<0,001 **
IV furosemide dose (mg/d)	75,80 ± 21,52	67,57 ± 25,54	0,001
Oral furosemide—%	0	63	—
Oral furosemide dose (mg/d)	0	74,6 ± 28,1	—
Furosemide dose reduction or oral route—%	—	84	—
ACEi—%	44	61	<0,001 **
Ramipril Eq. dose (mg/d)	3,15 ± 2,04	3,36 ± 2,14	0,474
Beta-blocker—%	37	57	<0,001 **
Bisoprolol Eq. dose (mg/d)	3,01 ± 1,08	2,96 ± 1,89	0,474
Spironolactone—%	50	50	1**
Spironolactone dose (mg/d)	94,50 ± 23,31	62,74 ± 24,33	<0,001

Continuous variables are presented as mean value ± standard deviation SD, value or median [interquartile range (IQR)], value. Categorical variables are presented as % of total (100 patients), value.
*Nonparametric paired sample test; **chi-square test.
COPD: chronic obstructive pulmonary disease; LV: left ventricular; eGFR: estimated glomerular filtration rate; NTproBNP: N-terminal probrain natriuretic peptide; hsTnT: high sensitivity troponin T; IV: intravenous; ACEi: angiotensin converting enzyme inhibitors.